Benutzerspezifische Werkzeuge


2022                 |<<

Korovina I, Vehlow A, Temme A, Cordes N.
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
Neuro Oncol. 2022 Oct 11:noac237. doi: 10.1093/neuonc/noac237.

Murad S, Michen S, Becker A, Füssel M, Schackert G, Tonn T, Momburg F, Temme A.
NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme.
Int J Mol Sci. 2022 May 23;23(10):5857. doi: 10.3390/ijms23105857.

Clausing M, William D, Preussler M, Biedermann J, Grützmann K, Richter S, Buchholz F, Temme A, Schröck E, Klink B.
Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
Int J Mol Sci. 2022 May 21;23(10):5787. doi: 10.3390/ijms23105787.

Jugel W, Tietze S, Daeg J, Appelhans D, Broghammer F, Aigner A, Karimov M, Schackert G, Temme A.
Targeted Transposition of Minicircle DNA Using Single-Chain Antibody Conjugated Cyclodextrin-Modified Poly (Propylene Imine) Nanocarriers.
Cancers (Basel). 2022 Apr 11;14(8):1925. doi: 10.3390/cancers14081925.

Rao VS, Gu Q, Tzschentke S, Lin K, Ganig N, Thepkaysone ML, Wong FC, Polster H, Seifert L, Seifert AM, Buck N, Riediger C, Weiße J, Gutschner T, Michen S, Temme A, Schneider M, Baenke F, Weitz J, Kahlert C.
Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases.
Oncogene. 2022 Mar;41(12):1809-1820. doi: 10.1038/s41388-022-02218-9.

2021                 |<<

Moreno S, Boye S, Ajeilat HGA, Michen S, Tietze S, Voit B, Lederer A, Temme A, Appelhans D.
Multivalent Protein-Loaded pH-Stable Polymersomes: First Step toward Protein Targeted Therapeutics.
Macromol Biosci. 2021 Aug 6:e2100102. doi: 10.1002/mabi.202100102.
Brock T, Boudriot E, Klawitter A, Großer M, Nguyen TTP, Giebe S, Klapproth E, Temme A, El-Armouche A, Breier G.
The Influence of VE-Cadherin on Adhesion and Incorporation of Breast Cancer Cells into Vascular Endothelium.
Int J Mol Sci. 2021 Jun 3;22(11):6049. doi: 10.3390/ijms22116049.
Jugel W, Aigner A, Michen S, Hagstotz A, Ewe A, Appelhans D, Schackert G, Temme A, Tietze S.
Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors.
Pharmaceutics. 2021 May 8;13(5):676. doi: 10.3390/pharmaceutics13050676.
Tietze S, Michen S, Schackert G, Temme A.
Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma.
Innov Surg Sci, 2021 Apr 16. doi: 10.1515/iss-2020-0034.
Scheuring UJ, Ritter S, Martin D, Schackert G, Temme A, Tietze S.
GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo.
J Neurooncol. 2021 Apr 15. doi: 10.1007/s11060-021-03737-3.

2020                 |<<

Sidorcenco V, Krahnen L, Schulz M, Remy J, Kögel D, Temme A, Krügel U, Franke H, Aigner A.
Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth.
Cancers (Basel). 2020 Sep 21;12(9):2707. doi: 10.3390/cancers12092707.
Seifert M, Schackert G, Temme A, Schröck E, Deutsch A, Klink B.
Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs. 
Cancers (Basel). 2020 Jun 26;12(6):1696. doi: 10.3390/cancers12061696.
Michen S, Frosch J, Füssel M, Schackert G, Momburg F, Temme A.
Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self. 
Cytotherapy. 2020 Jul;22(7):354-368. doi: 10.1016/j.jcyt.2020.02.004. Epub 2020 May 23.
Meneceur S, Linge A, Meinhardt M, Hering S, Löck S, Bütof R, Krex D, Schackert G, Temme A, Baumann M, Krause M, von Neubeck C.
Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. 
Cancers (Basel). 2020 Apr 3;12(4):871. doi: 10.3390/cancers12040871.
Müller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D, Meier F, Bachmann M, Schmitz M.
Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. 
Front Immunol. 2020 Feb 5;11:140. doi: 10.3389/fimmu.2020.00140. eCollection 2020.
Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M.
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4.

2019                 |<<

Biedermann J, Preussler M, Conde M, Peitzsch M, Richter S, Wiedemuth R, Abou-El-Ardat K, Krüger A, Meinhardt M, Schackert G, Leenders WP, Herold-Mende C, Niclou SP, Bjerkvig R, Eisenhofer G, Temme A, Seifert M, Kunz-Schughart LA, Schröck E, Klink B.
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Cancers (Basel). 2019 Dec 16;11(12). pii: E2028. doi: 10.3390/cancers11122028.
Daeg J, Xu X, Zhao L, Boye S, Janke A, Temme A, Zhao J, Lederer A, Voit B, Shi X, Appelhans D.
Bivalent Peptide- and Chelator-Containing Bioconjugates as Toolbox Components for Personalized Nanomedicine.
Biomacromolecules. 2019 Nov 4. doi: 10.1021/acs.biomac.9b01127.
Fingernagel J, Boye S, Kietz A, Höbel S, Wozniak K, Moreno S, Janke A, Lederer A, Aigner A, Temme A, Voit B, Appelhans D.
Mono- and Polyassociation Processes of Pentavalent Biotinylated PEI Glycopolymers for the Fabrication of Biohybrid Structures with Targeting Properties.
Biomacromolecules. 2019 Sep 9;20(9):3408-3424. doi: 10.1021/acs.biomac.9b00667. Epub 2019 Aug 7.
Vehlow A, Klapproth E, Jin S, Hannen R, Hauswald M, Bartsch JW, Nimsky C, Temme A, Leitinger B, Cordes N.
Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity.
Cell Rep. 2019 Mar 26;26(13):3672-3683.e7. doi: 10.1016/j.celrep.2019.02.096.
Schau I, Michen S, Hagstotz A, Janke A, Schackert G, Appelhans D, Temme A.
Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis.
Sci Rep. 2019 Mar 1;9(1):3299. doi: 10.1038/s41598-019-40032-8.
Doi N, Kunimatsu Y, Fujiura K, Togari H, Minagi K, Nakaoji K, Hamada K, Temme A, Tatsuka M.
RhoGDIβ affects HeLa cell spindle orientation following UVC irradiation.
J Cell Physiol. 2019 Jan 16. doi: 10.1002/jcp.28154.

2018                 |<<

Liebig F, Moreno S, Thünemann AF, Temme A, Appelhans D, Koetz J.
Toxicological investigations of "naked" and polymer-entrapped AOT-based gold nanotriangles.
Colloids Surf B Biointerfaces. 2018 Jul 1;167:560-567. doi: 10.1016/j.colsurfb.2018.04.059. Epub 2018 Apr 30. PMID: 29734066.
Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Biomedicines. 2018 Mar 1;6(1). pii: E26. doi: 10.3390/biomedicines6010026. Review.
Sanchez D, Luksch H, Sifringer M, Temme A, Staufner C, Rzeski W, Grabarska A, Ikonomidou C, Stepulak A.
AMPA receptor antagonist CFM-2 decreases survivin expression in cancer cells.
Anticancer Agents Med Chem. 2018 Feb 28. doi: 10.2174/1871520618666180228123406.
Tienken L, Drude N, Schau I, Winz OH, Temme A, Weinhold E, Mottaghy FM, Morgenroth A.
Evaluation of a Pretargeting Strategy for Molecular Imaging of the Prostate Stem Cell Antigen with a Single Chain Antibody.
Sci Rep. 2018 Feb 28;8(1):3755. doi: 10.1038/s41598-018-22179-y.

2017                 |<<

Conde M, Michen S, Wiedemuth R, Klink B, Schröck E, Schackert G, Temme A.
Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
BMC Cancer. 2017 Dec 28;17(1):889. doi: 10.1186/s12885-017-3932-y.
Uckermann O, Juratli TA, Galli R, Conde M, Wiedemuth R, Krex D, Geiger KD, Temme A, Schackert G, Koch E, Steiner G, Kirsch M.
Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
Clin Cancer Res. 2017 Dec 19. pii: clincanres.1795.2017. doi: 10.1158/1078-0432.CCR-17-1795.
Huebner D, Rieger C, Bergmann R, Ullrich M, Meister S, Toma M, Wiedemuth R, Temme A, Novotny V, Wirth MP, Bachmann M, Pietzsch J, Fuessel S.
An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
BMC Cancer. 2017 Nov 23;17(1):790. doi: 10.1186/s12885-017-3778-3.
Hinrichs CN, Ingargiola M, Käubler T, Löck S, Temme A, Köhn-Luque A, Deutsch A, Vovk O, Stasyk O, Kunz-Schughart LA.
Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization.
Mol Cancer Ther. 2017 Aug 22. pii: molcanther.0807.2016. doi: 10.1158/1535-7163.MCT-16-0807.
Tietze S, Schau I, Michen S, Ennen F, Janke A, Schackert G, Aigner A, Appelhans D, Temme A.
A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of siRNA.
Small. 2017 May 22. doi: 10.1002/smll.201700072.
Vehlow A, Klapproth E, Storch K, Dickreuter E, Seifert M, Dietrich A, Bütof R, Temme A, Cordes N.
Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.
Oncotarget. 2017 Apr 27. doi: 10.18632/oncotarget.17480.
Abou-El-Ardat K, Seifert M, Becker K, Eisenreich S, Lehmann M, Hackmann K, Rump A, Meijer G, Carvalho B,
Temme A, Schackert G, Schröck E, Krex D, Klink B.
Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
Neuro Oncol. 2017 Feb 13. doi: 10.1093/neuonc/now231.

2016                 |<<

Michen S, Temme A
Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy. Crit Rev Immunol. 2016;36(4): 329-47. doi: 10.1615/CritRevImmunol.v36.i4.
Galli R, Uckermann O, Temme A, Leipnitz E, Meinhardt M, Koch E, Schackert G, Steiner G, Kirsch M.
Assessing the efficacy of coherent anti-Stokes Raman scattering microscopy for the detection of infiltrating glioblastoma in fresh brain samples.J Biophotonics. 2016 Mar 11. doi: 10.1002/jbio.201500323.
Ewe A, Panchal O, Pinnapireddy SR, Bakowsky U, Przybylski S, Temme A, Aigner A.Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo.Nanomedicine. 2016 Aug 20. pii: S1549-9634(16)30113-7. doi: 10.1016/j.nano.2016.08.005.
Wiedemuth R, Klink B, Fujiwara M, Schröck E, Tatsuka M, Schackert G, Temme A.
Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny.
Carcinogenesis. 2016 Aug 11. pii: bgw083.
Temme A, Schmitz M.
Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.
Immunotherapy. 2016 Sep;8(9):983-6. doi: 10.2217/imt-2016-0072.
Galli R, Uckermann O, Temme A, Leipnitz E, Meinhardt M, Koch E, Schackert G, Steiner G, Kirsch M.
Assessing the efficacy of coherent anti-Stokes Raman scattering microscopy for the detection of infiltrating glioblastoma in fresh brain samples.
J. Biophotonics 2016, 1–11, DOI 10.1002/jbio.201500323.
Fujiwara M, Okamoto M, Hori M, Suga H, Jikihara H, Sugihara Y, Shimamoto F, Mori T, Nakaoji K, Hamada K, Ota T, Wiedemuth R, Temme A, Tatsuka M.
Radiation-Induced RhoGDIβ Cleavage Leads to Perturbation of Cell Polarity: A Possible Link to Cancer Spreading.
J Cell Physiol. 2016 Feb 25. doi: 10.1002/jcp.25362.

2015                 |<<

Hausmann C, Temme A, Cordes N, Eke I.
ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.
Oncotarget. 2015 Oct 27;6(33):34592-605. doi: 10.18632/oncotarget.5423.
Carvalhal S, Ribeiro SA, Arocena M, Kasciukovic T, Temme A, Koehler K, Huebner A, Griffis ER.
The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation.
Mol Biol Cell. 2015 Oct 1;26(19):3424-38. doi: 10.1091/mbc.E15-02-0113. Epub 2015 Aug 5.
Rieger C, Huebner D, Temme A, Wirth MP, Fuessel S.
Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells.
Int J Oncol. 2015 Sep;47(3):1121-30. doi: 10.3892/ijo.2015.3096. Epub 2015 Jul 20.
Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A.
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
J Immunother. 2015 Jun;38(5):197-210. doi: 10.1097/CJI.0000000000000082.
Töpfer K, Cartellieri M, Michen S, Wiedemuth R, Müller N, Lindemann D, Bachmann M, Füssel M, Schackert G,
Temme A.
DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
J Immunol. 2015 Apr 1;194(7):3201-12. doi: 10.4049/jimmunol.1400330. Epub 2015 Mar 4.
Yassin MA, Appelhans D, Wiedemuth R, Formanek P, Boye S, Lederer A, Temme A, Voit B.
Overcoming concealment effects of targeting moieties in the PEG corona: controlled permeable polymersomes decorated with folate-antennae for selective targeting of tumor cells.
Small. 2015 Apr;11(13):1580-91. doi: 10.1002/smll.201402581. Epub 2014 Oct 31.

2014     <<          |<<

Okamoto M, Fujiwara M, Hori M, Okada K, Yazama F, Konishi H, Xiao Y, Qi G, Shimamoto F, Ota T, Temme A,
Tatsuka M.
tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells.
PLoS Genet. 2014 Sep 18;10(9):e1004639. doi: 10.1371/journal.pgen.1004639. eCollection 2014 Sep.
Arndt C, Feldmann A, Töpfer K, Koristka S, Cartellieri M, Temme A, Ehninger A, Ehninger G, Bachmann M.
Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Prostate. 2014 Sep;74(13):1347-58. doi: 10.1002/pros.22851. Epub 2014 Jul 22.
Martin DK, Uckermann O, Bertram A, Liebner C, Hendruschk S, Sitoci-Ficici KH, Schackert G, Lord EM, Temme A, Kirsch M.
Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.
Anticancer Res. 2014 Jul;34(7):3293-302.
Wiedemuth R, Klink B, Töpfer K, Schröck E, Schackert G, Tatsuka M, Temme A.
Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53.
Mol Cancer. 2014 May 9;13:107. doi: 10.1186/1476-4598-13-107.
Koristka S, Cartellieri M, Arndt C, Feldmann A, Töpfer K, Michalk I, Temme A, Ehninger G, Bachmann M.
Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity.
Blood Cancer J. 2014 Apr 11;4:e199. doi: 10.1038/bcj.2014.20.
Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, Töpfer K, Krüger T, Geib M, Michalk I,
Temme A, Bornhäuser M, Lindemann D, Ehninger G, Bachmann MP.
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells.
PLoS One. 2014 Apr 3;9(4):e93745. doi: 10.1371.
Ewe A, Schaper A, Barnert S, Schubert R, Temme A, Bakowsky U, Aigner A.
Storage stability of optimal liposome-polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery.
Acta Biomater. 2014 Mar 1. pii: S1742-7061(14)00089-0. doi: 10.1016/j.actbio.2014.02.037.

 2013     <<          |<<

Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A, Tatsuka M.
The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer.
PLoS One. 2013;8(2):e55710. doi: 10.1371/journal.pone.0055710

 2012     <<          |<<

Huang X, Hauptmann N, Appelhans D, Formanek P, Frank S, Kaskel S, Temme A, Voit B.
Synthesis of hetero-polymer functionalized nanocarriers by combining surface-initiated ATRP and RAFT polymerization.
Small. 2012 Dec 7;8(23):3579-83. doi: 10.1002/smll.201201397. Epub 2012 Aug 22
Eke I, Storch K, Kästner I, Vehlow A, Faethe C, Mueller-Klieser W, Taucher-Scholz G, Temme A, Schackert G,
Cordes N.
Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation
in vitro.
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e515-23. doi: 10.1016/j.ijrobp.2012.06.012.
Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, Temme A, Bornhäuser M, Ehninger G, Bachmann M.
Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells.
J Immunol. 2012 Sep 15;189(6):3249-59.

 2011     <<          |<<

Töpfer K, Kempe S, Müller N, Schmitz M, Bachmann M, Cartellieri M, Schackert G, Temme A.
Tumor evasion from T cell surveillance.
J Biomed Biotechnol. 2011;2011:918471. doi: 10.1155/2011/918471.
Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, Michalk I, Töpfer K, Temme A, Kretschmer K, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M.
Retargeting of human regulatory T cells by single-chain bispecific antibodies.
J Immunol. 2012 Feb 1;188(3):1551-8.
Oppel F, Müller N, Schackert G, Hendruschk S, Martin D, Geiger KD, Temme A.
SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells.
Mol Cancer. 2011 Nov 9;10:137. doi: 10.1186/1476-4598-10-137.
Luksch H, Uckermann O, Stepulak A, Hendruschk S, Marzahn J, Bastian S, Staufner C, Temme A, Ikonomidou C.
Silencing of selected glutamate receptor subunits modulates cancer growth.
Anticancer Res. 2011 Oct;31(10):3181-92.
Hendruschk S, Wiedemuth R, Aigner A, Töpfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C, Schackert G, Temme A.
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo.
Neuro Oncol. 2011 Oct;13(10):1074-89.
Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G.
Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.
Cancer Gene Ther. 2011 Aug;18(8):598-608.
Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M.
Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.
Prostate. 2011 Jun 15;71(9):998-1011.
Geiger KD, Hendruschk S, Rieber EP, Morgenroth A, Weigle B, Juratli T, Senner V, Schackert G, Temme A.
The prostate stem cell antigen represents a novel glioma-associated antigen.
Oncol Rep. 2011 Jul;26(1):13-21. doi: 10.3892/or.2011.1265.
Bippes CC, Feldmann A, Stamova S, Cartellieri M, Schwarzer A, Wehner R, Schmitz M, Rieber EP, Zhao S, Schäkel K, Temme A, Scofield RH, Kurien BT, Bartsch H, Bachmann M.
A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs).
PLoS One. 2011 Jan 21;6(1):e16315. doi: 10.1371/journal.pone.0016315.

 2010     <<          |<<

Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, Hazelwood L, Olsson A, Volkmann N, Hanein D, Freeze HH.
Carboxylated N-glycans on RAGE promote S100A12 binding and signaling.
J Cell Biochem. 2010 Jun 1;110(3):645-59.
Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M.
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
Biomed Biotechnol. 2010;2010:956304. doi: 10.1155/2010/956304.
Temme A, Geiger KD, Wiedemuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G, Tatsuka M, Hagel C,
Westphal M, Berger H, Simon M, Weller M, Schackert G.
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation.
J Neuropathol Exp Neurol. 2010 Jun;69(6):632-42.
Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, Schackert G, Temme A, Ikonomidou C.
Glutamate receptors in pediatric tumors of the central nervous system.
Cancer Biol Ther. 2010 Mar 15;9(6):455-68.

 2007     <<          |<<

Kiani A, Kuithan H, Kuithan F, Kyttälä S, Habermann I, Temme A, Bornhäuser M, Ehninger G.
Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells: regulation of Fas ligand gene expression in megakaryocytes.
Exp Hematol. 2007 May;35(5):757-70.
Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A.
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Prostate. 2007 Jul 1;67(10):1121-31.
Temme A, Rodriguez JA, Hendruschk S, Günes S, Weigle B, Schäkel K, Schmitz M, Bachmann M,
Schackert G, Rieber EP.
Nuclear localization of Survivin renders HeLa tumor cells more sensitive to apoptosis by induction of p53 and Bax.
Cancer Lett. 2007 Jun 8;250(2):177-93. Epub 2006 Nov 7.

 2006     <<          |<<

Rohayem J, Jäger K, Robel I, Scheffler U, Temme A, Rudolph W.
Characterization of norovirus 3Dpol RNA-dependent RNA polymerase activity and initiation of RNA synthesis.
J Gen Virol. 2006 Sep;87(Pt 9):2621-30.
Schmitz M, Wehner R, Stevanovic S, Kiessling A, Rieger MA, Temme A, Bachmann M, Rieber EP, Weigle B.
Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11.
Cancer Lett. 2007 Jan 8;245(1-2):331-6. Epub 2006 Feb 28.
McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary JP, Moumdjian R, Béliveau R.
The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate.
Brain Res. 2006 Feb 3;1071(1):1-9. Epub 2006 Jan 10.

 2005     <<          |<<

Schmitz M, Zhao S, Deuse Y, Schäkel K, Wehner R, Wöhner H, Hölig K, Wienforth F, Kiessling A, Bornhäuser M, Temme A, Rieger MA, Weigle B, Bachmann M, Rieber EP.
Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity.
J Immunol. 2005 Apr 1;174(7):4127-34.
Kiessling A, Weigle B, Fuessel S, Ebner R, Meye A, Rieger MA, Schmitz M, Temme A, Bachmann M, Wirth MP,
Rieber EP.
D-TMPP: a novel androgen-regulated gene preferentially expressed in prostate and prostate cancer that is the first characterized member of an eukaryotic gene family.
Prostate. 2005 Sep 1;64(4):387-400.
Temme A, Diestelkoetter-Bachert P, Schmitz M, Morgenroth A, Weigle B, Rieger MA, Kiessling A, Rieber EP.
Increased p21(ras) activity in human fibroblasts transduced with survivin enhances cell proliferation.
Biochem Biophys Res Commun. 2005 Feb 18;327(3):765-73.
Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, Rieger MA, Schackert G, Schackert HK, Rieber EP.
Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas.
Oncol Rep. 2005 Jan;13(1):139-44.

 2004     <<          |<<

Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP.
D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate.
Biochem Biophys Res Commun. 2004 Sep 10;322(1):239-49.
Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M, Temme A, Rieber EP, Weigle B.
Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.
Cancer Res. 2004 Apr 1;64(7):2357-64.
Weigle B, Kiessling A, Ebner R, Fuessel S, Temme A, Meye A, Schmitz M, Rieger MA, Ockert D, Wirth MP, Rieber EP.
D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer.
Int J Cancer. 2004 May 10;109(6):882-92.

 2003     <<          |<<

Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP.
Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell.
Mol Biol Cell. 2003 Jan;14(1):78-92.

 2002     <<          |<<

Evert M, Ott T, Temme A, Willecke K, Dombrowski F.
Morphology and morphometric investigation of hepatocellular preneoplastic lesions and neoplasms in connexin32-deficient mice.
Carcinogenesis. 2002 May;23(5):697-703.